Target intelligence / Profile preview

Factor inhibiting hypoxia-inducible factor (FIH)

Target
FIH
Molecular classification
Enzyme, 2-oxoglutarate-dependent dioxygenase, Asparaginyl hydroxylase
01

Overview

Factor inhibiting hypoxia-inducible factor (FIH) is a 2-oxoglutarate and Fe(II)-dependent dioxygenase enzyme that catalyzes the hydroxylation of a conserved asparagine residue within the C-terminal transactivation domain of HIF-α proteins, restricting their ability to interact with transcriptional coactivators and thereby repressing HIF-mediated transcriptional activity under normal oxygen conditions (normoxia). FIH acts as a cellular oxygen sensor and regulates transcriptional responses to hypoxia. Apart from HIF-α, FIH also modifies proteins containing ankyrin repeat domains, though the biological significance of these modifications remains partly unresolved. Due to its central role in oxygen-dependent gene regulation, FIH is being explored as a drug target in diseases such as cancer and ischemia, where hypoxia and metabolic regulation are critical.

Other names
FIHFIH-1Factor-inhibiting HIF-1Asparaginyl hydroxylase
02

Mechanism of action

Inhibition of FIH enzymatic activity (asparaginyl hydroxylase), resulting in reduced hydroxylation of HIF-α, enhanced HIF-α transcriptional activity, and upregulated cellular hypoxic response Modulation of oxygen sensing and adaptation via alteration of HIF target gene expression

03

Biological functions

Oxygen sensingRegulation of hypoxia-inducible factors (HIFs)Regulation of cellular response to hypoxiaRegulation of transcriptional activityPost-translational protein modification (asparaginyl hydroxylation)Hydroxylation of ankyrin repeat domain proteins
04

Disease associations

CancerIschemic diseaseInflammatory diseaseMetabolic disorders
05

Safety considerations

Therapeutic inhibition may promote excessive angiogenesis or tumor growth via uncontrolled HIF activationPotential off-target effects due to wide substrate specificity (e.g., ankyrin repeat domain proteins)Unclear clinical safety profiles due to lack of approved FIH-targeting drugs
06

Interacting drugs

Small molecule inhibitors targeting 2-oxoglutarate binding (e.g., N-oxaloylglycine, designed hydroxylase inhibitors under preclinical investigation)

1 more in the full profile.

07

Biomarkers

Hydroxylation status of HIF-α asparagine residueExpression levels of HIF target genes (e.g., VEGF, glycolytic enzymes)Hydroxylation status of ankyrin repeat domain proteins

Beyond the preview

Go deeper on Factor inhibiting hypoxia-inducible factor (FIH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Factor inhibiting hypoxia-inducible factor (FIH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call